OVERVIEW
Cardiointegram (CIG) is a technique intended to detect abnormalities in the standard 12-lead electrocardiogram in patients at risk of cardiac ischemia.

This policy is applicable to Commercial Products only. For BlueCHiP for Medicare, see Related Policy section.

MEDICAL CRITERIA
Not applicable

PRIOR AUTHORIZATION
Not applicable

POLICY STATEMENT
Commercial Products
Cardiointegram is not medically necessary as the evidence is insufficient to determine the effects of the technology on health outcomes.

COVERAGE
Benefits may vary between groups and contracts. Please refer to the appropriate section of the Benefit Booklet, Evidence of Coverage or Subscriber Agreement for applicable not medically necessary benefits/coverage.

BACKGROUND
A cardiointegram device consists of a microcomputer that receives output from a standard electrocardiogram (EKG) and transforms it to produce a graphic representation of heart electrophysiologic signals. This procedure may be used as a substitute for exercise tolerance testing with thallium imaging in patients for whom a resting EKG may be inadequate to identify changes compatible with coronary artery disease.

Cardiointegram, a technique intended to detect abnormalities in the standard 12-lead electrocardiogram that are not identifiable by competent routine interpretation in patients at risk of cardiac ischemia, is considered not medically necessary because there is insufficient evidence to support conclusions regarding its efficacy as a diagnostic tool.

CODING
Commercial Products
The following code is not medically necessary:
S9025 Omnicardiogram/cardiointegram

RELATED POLICIES
BlueCHiP for Medicare National and Local Coverage Determinations

PUBLISHED
Provider Update, April 2020
REFERENCES